Genmab — April 2017
-
Bulder@ Det bliver interessant med SH-tallene, og om de 5 % stadig holder, eller om forskellen skal justeres fremadrettet.
-
Revenue was crimped by slower growth in many consumer health product categories and by payers demanding bigger rebates off the prices of certain prescription drugs, Chief Financial Officer Dominic Caruso said in an interview. Caruso said drugs with significant competition, particularly cardiovascular, diabetes and other primary care drugs, were particularly hurt by the pricing pressure.
"The diabetes market is very price sensitive, and (net) prices have been declining for some time"
-
Det er "dagligvarerne" som presses i pris - ikke specialprodukterne.
-
@bibob: HØRT!!!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
